Gambaran Umum
Elicio Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing primarily on developing immunotherapies for cancer treatment. The company leverages its proprietary Amphiphile technology to enhance the immune system's response against cancerous cells. A key project includes their lead product candidate, ELI-002, an investigational therapeutic vaccine targeting KRAS-driven cancers, which are prevalent and typically aggressive. This vaccine aims to stimulate robust immune responses against multiple KRAS mutations simultaneously, addressing a significant unmet need in oncology. Elicio's innovative approach in immuno-oncology underscores its commitment to advancing cancer treatments through targeted therapies and vaccine development.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Elicio Therapeutics, Inc. per 2025 Jun 30 adalah -44.65 MM.
- Nilai net income untuk Elicio Therapeutics, Inc. per 2025 Jun 30 adalah -54.61 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -44.65 | -54.61 | |
2025-03-31 | -45.48 | -51.28 | |
2024-12-31 | -44.99 | -51.90 | |
2024-09-30 | -40.90 | -46.84 | |
2024-06-30 | -41.33 | -38.66 | |
2024-03-31 | -38.18 | -38.99 | |
2023-12-31 | -35.74 | -35.20 | |
2023-09-30 | -32.31 | -32.90 | |
2023-06-30 | -27.31 | -29.43 | |
2023-03-31 | -25.77 | -29.18 | |
2022-12-31 | -23.73 | -28.21 | |
2022-09-30 | -23.45 | -28.17 | |
2022-03-31 | -25.05 | -27.27 | |
2021-12-31 | -25.47 | -26.40 | |
2021-03-31 | -18.90 | -18.90 | |
2020-12-31 | -15.72 | -15.71 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -4.29 | -4.29 |
2024-06-30 | -4.01 | -4.01 |
2024-03-31 | -5.17 | -5.17 |
2023-12-31 | -6.96 | |
2023-09-30 | -10.96 | -10.96 |
2023-06-30 | -30.43 | -30.43 |
2023-03-31 | -1.61 | -1.61 |
2022-12-31 | -89.27 | |
2022-09-30 | -6.23 | -6.23 |
2022-03-31 | -1.68 | -1.68 |
2021-12-31 | -1.73 | |
2021-03-31 | -1.53 | -1.53 |
2020-12-31 | -1.46 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Elicio Therapeutics, Inc. per 2025 Jun 30 adalah -35.09 MM.
- Nilai cash from investing activities untuk Elicio Therapeutics, Inc. per 2025 Jun 30 adalah -0.04 MM.
- Nilai kas dari aktivitas pendanaan untuk Elicio Therapeutics, Inc. per 2025 Jun 30 adalah 53.24 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -35.09 | -0.04 | 53.24 |
2025-03-31 | -35.06 | -0.09 | 41.62 |
2024-12-31 | -37.07 | -0.08 | 42.32 |
2024-09-30 | -38.22 | -0.04 | 49.09 |
2024-06-30 | -36.13 | -0.08 | 18.40 |
2024-03-31 | -36.68 | -0.01 | 39.60 |
2023-12-31 | -32.69 | -0.03 | 38.61 |
2023-09-30 | -30.07 | -0.13 | 42.79 |
2023-06-30 | -30.28 | -0.08 | 51.51 |
2023-03-31 | -25.08 | -0.17 | 31.24 |
2022-12-31 | -22.18 | -0.65 | 21.20 |
2022-09-30 | -21.01 | -0.69 | 24.06 |
2022-03-31 | -23.11 | -0.95 | 14.28 |
2021-12-31 | -23.94 | -0.53 | 19.39 |
2021-03-31 | -20.27 | -0.21 | 22.66 |
2020-12-31 | -16.70 | -0.20 | 25.06 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah 13.85.
- p/tbv untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah 13.85.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 13.85 | 13.85 | |
2025-03-31 | -6.50 | -6.50 | |
2024-12-31 | -2.84 | -2.84 | |
2024-09-30 | -1.41 | -32.96 | -32.96 |
2024-06-30 | -1.81 | 14.51 | 14.51 |
2024-03-31 | -2.18 | 5.39 | 5.39 |
2023-12-31 | -2.12 | 5.26 | 5.26 |
2023-09-30 | -2.29 | 2.86 | 2.86 |
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-03-31 | |||
2020-12-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah -0.41.
- EBIT (3 tahun) / EV untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah -0.32.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.41 | -0.32 |
2025-03-31 | -0.40 | -0.33 |
2024-12-31 | -0.98 | -0.77 |
2024-09-30 | -0.76 | -0.65 |
2024-06-30 | -0.66 | -0.39 |
2024-03-31 | -0.57 | -0.35 |
2023-12-31 | -0.59 | -0.31 |
2023-09-30 | -0.64 | -0.21 |
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-03-31 | ||
2020-12-31 |
Efektivitas Manajemen
- roa untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah -3.26.
- roic untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah -1.48.
- croic untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah 0.19.
- ocroic untuk Elicio Therapeutics, Inc. pada 2025 Jun 30 adalah -1.01.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -3.26 | -1.48 | 0.19 | -1.01 | |
2025-03-31 | -1.91 | -9.62 | -6.63 | 1.53 | -5.41 |
2024-12-31 | -1.73 | -4.12 | -6.63 | 1.53 | -5.41 |
2024-09-30 | -1.25 | -2.91 | -8.11 | -3.74 | -7.58 |
2024-06-30 | -1.53 | -32.93 | -2.01 | 0.15 | -1.89 |
2024-03-31 | -1.45 | -3.69 | -1.69 | 1.08 | -1.55 |
2023-12-31 | -1.61 | 0.61 | -1.47 | ||
2023-09-30 | -0.95 | 0.68 | -0.98 | ||
2023-06-30 | -0.95 | 0.68 | |||
2023-03-31 | -3.43 | 0.71 | |||
2022-12-31 | |||||
2022-09-30 | |||||
2022-03-31 | -1.75 | ||||
2021-12-31 | 0.00 | ||||
2021-03-31 | -2.14 | -2.84 | -1.19 | 0.14 | -1.28 |
2020-12-31 | -1.78 | -2.36 | -0.94 | 0.49 | -0.99 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-03-31 | |||
2020-12-31 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1601485 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |